Dna Group (DNA) Fair Value & Analysis
Consumer Cyclical · Il · Market cap 921M ILA
Fair value as of: Jul 19, 2026
From 19 valuation models · updated 22 days ago
Share price −11.9% over the past month.
A solid business, but screening 73% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.3000 ILA). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 19, 2026.
How to read this chart
60‑month range 0.5527 ILA – 1.82 ILA · fair‑value band 0.2400 ILA – 0.3000 ILA · the 0.9910 ILA price screens above the 0.2700 ILA fair value. Dashed = 300-day average. As of Jul 19, 2026.
Analysis
Dna Group (DNA) currently trades at 0.9910 ILA, while our model-based Fair Value estimate is 0.2700 ILA, implying the stock looks roughly 72.8% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Trailing-twelve-month revenue stands at 306K ILA. It earns a return on equity of 0.5%. The balance sheet holds a net cash position of 68.3M ILA. Fundamentals as of Jul 19, 2026
Our scenario range runs from 0.2400 ILA (bear case) to 0.3000 ILA (bull case); at 0.9910 ILA, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Consumer Cyclical peers we cover trades at -62% fair-value upside, at -73%, DNA screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 19 models by family
Widest divergence: Growth Earnings (0.4000 ILA) versus Asset-Based (0.0800 ILA). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 42
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children.
Full company description
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Dna Group reported revenue of 306K ILA in FY2024 versus 0 ILA in FY2020. Reported net income was 22.1M ILA in FY2024.
DNA screens 73% overvalued. Compare with Marriott International, Inc →
Peer Group
Lodging · 170 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Lodging median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Lodging stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Marriott International, Inc MAR | $369.05 | $135.64 | -63% |
| Hilton Worldwide Holdings HLT | $328.48 | $123.67 | -62% |
| InterContinental Hotels Group IHG | $159.87 | $85.18 | -47% |
| Hyatt Hotels Corporation H | $191.00 | $47.69 | -75% |
| H World Group HTHT | $42.67 | $47.55 | +11% |
| Accor SA AC | €47.25 | €39.26 | -17% |
| The Indian Hotels Company INDHOTEL | ₹743.20 | ₹260.68 | -65% |
| Wyndham Hotels & Resorts, Inc WH | $78.54 | $24.02 | -69% |
| Hanjin Kal, 180640 | 113,500 KRW | 36,890 KRW | -67% |
| Jabal Omar Development Company 4250 | 16.00 SAR | 11.64 SAR | -27% |
Compare Dna Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Frequently asked questions
Is Dna Group (DNA) overvalued or undervalued?
What is the fair value of DNA?
What is the quality score of DNA?
What is the revenue of Dna Group (DNA)?
What is the net profit margin of DNA?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Dna Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.